Shree Ganesh Remedies Ltd
P&L
Quarterly Consolidated
vs Q2 FY25
Shree Ganesh Remedies Limited Reports Q3 & 9MFY25 Results: Revenue Down 3% YoY, PAT Up 13% YoY
06 Feb 2025 · 6 Feb 2025, 02:32 am
Summary
Shree Ganesh Remedies Limited, a leading player in the chemical manufacturing industry, announced its financial results for Q3 & 9MFY25. The company experienced a 3% YoY decline in revenue due to intensified domestic competition for traditional products, but achieved robust growth in volumes. The decline in profitability from traditional products was offset by high margins from CRAMS projects. The ramp-up of Block 8 is progressing according to plan, and a maintenance and refurbishment shutdown of Block 3 is underway. A new block, Block 7, is expected to be completed by the end of Q4FY26 and initiate commercial production in QT1FY27. The company also announced an R&D block at its existing site and a Long-Term Strategic Supply Agreement with a leading Japanese company for manufacturing specialty chemicals.
Key Highlights
- 1
Revenue down 3% YoY, PAT up 13% YoY
- 2
Robust growth in volumes during Q3FY25
- 3
High margins from CRAMS projects offset decline in traditional products profitability
- 4
Maintenance and refurbishment shutdown of Block 3
- 5
Construction of new Block 7 and R&D block underway
- 6
Long-Term Strategic Supply Agreement with a leading Japanese company
Management Comments
Mr. Gunjan Kothia
Promoter, Whole-Time Director
Commenting on the results, Mr. Gunjan Kothia, Promoter, Whole-Time Director, said: | am pleased to share our performance update for Q3FY25. In this quarter, we experienced a decline in revenue due to intensified domestic competition for our traditional products, which led to price reductions and impacted profitability. However, it is noteworthy that we achieved robust growth in volumes during this period. The decline in profitability from traditional products was effectively offset by the high margins generated from our CRAMS projects, as previously guided. On the operational front, the ramp-up of Block 8 is progressing according to plan, and we anticipate reaching optimal capacity utilisation by early next financial year. Leveraging this steady ramp-up, we have decided to undertake a maintenance and refurbishment shutdown of Block 3 during the current quarter. While this shutdown means we do not foresee volumetric growth for this quarter, we are well- positioned to manage the volume decline from Block 3 with the increased output from Block 8. Furthermore, | am pleased to announce that the designing phase of Block 7 has been completed, and construction activities have commenced. We expect to complete this new block by the end of Q4FY26 and initiate commercial production in QIFY27. Additionally, recognising the strong opportunities ahead, we are intensifying our R&D efforts by adding an R&D block at our existing site. The design work is currently underway, and construction will begin shortly. A significant highlight of this quarter is our recent Memorandum of Understanding (MOU) with a leading Japanese company. This Long-Term Strategic Supply Agreement marks a pivotal step in our strategic contract manufacturing venture within the specialty chemicals market. Under this agreement, we will manufacture three innovative products that will be introduced as the first of their kind in India. This partnership not only showcases our capabilities but also positions us to meet growing international market demands effectively.
Informational and educational content only. Not investment advice.